TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05502380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard antibiotic prophylaxis
Description: One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic prophylaxis
Description: One to three intravenous doses of cefuroxime 1.5 g intravenously; or 3g if obesity; or vancomycin 1 g or clindamycin 600 mg; if allergy. Continuation of eventual current therapeutic antibiotc regimens for any infection
Study: NCT05926765

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV2-hAQP1 Concentration 1
Description: Administration of concentration 1 of AAV2-hAQP1 via Stensen's duct to each parotid gland

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV2-hAQP1 Concentration 2
Description: Administration of concentration 2 of AAV2-hAQP1 via Stensen's duct to each parotid gland

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of diluent via Stensen's duct to each parotid gland
Study: NCT05555485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous Auricular neurostimulation - Active
Description: Active auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX). The tAN devices are portable, wearable systems with two channels of stimulation (auricular vagus and auricular trigeminal). Two individual stimulation frequencies will be set: 15 Hz at cymba concha (Region1/Channel 1; vagal innervation) and 100 Hz adjacently anterior to the tragus (Region 2/Channel 2; trigeminal innervation). The pulse duration will be set at 250 µs for all participants. The stimulation intensities (mA) will be set at 1.0 and 1.4 (for Regions 1 and 2, respectively) based on values observed in previous clinical studies. If the participant states that the stimulation intensity is discomforting or unperceivable, the study personnel will gradually decrease/increase the intensity until a comfortable stimulation intensity is achieved

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous auricular neurostimulation - Sham
Description: Sham auricular stimulation will be conducted using the FDA-cleared tAN device (Sparrow®) manufactured by Spark Biomedical (Dallas, TX) but will not deliver prolonged stimulation.
Study: NCT05167747

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement
Description: Dietary supplement formulated with magnesium, standardized extract of orthosiphon, standardized extract of hawthorn and standardized extract of hibiscus. Each tablet contains: 0.1 g magnesium, 0.25 g standardized extract of orthosiphon (Orthosiphon stamineus Benth), 0.16 standardized extract of hawthorn (Crataegus curvisepala Lind.) and 0.08 g standardized extract of hibiscus (Hibiscus sabdariffa L.).~Oral administration: 2 tablets/day at evening meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration: 2 tablets/day at evening meal
Study: NCT05239702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR T-cells
Description: Each subject receive CD7 CAR T-cells by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR T-cells
Description: Each subject receive CD7 CAR T-cells by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR T-cells
Description: Each subject receive CD7 CAR T-cells by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR T-cells
Description: Each subject receive CD7 CAR T-cells by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR T-cells
Description: Each subject receive CD7 CAR T-cells by intravenous infusion
Study: NCT05072314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2% and 10%
Description: Lidocaine infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).\*~2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.\*~2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only
Study: NCT06523725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PO BRC-003 (High Cannabidiol Cannabis Extract)
Description: The research is divided into two phases: an open-label dose-finding phase (Part A) and a subsequent randomized controlled phase (Part B).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05756439

Intervention type: DRUG
Intervention: Intravenous Sedatives with or Without Analgesia
Description: Participants having dental surgery with conscious intravenous sedation

Intervention type: DRUG
Intervention: No IV sedation
Description: Participants having dental surgery without conscious intravenous sedation
Study: NCT06629480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir
Description: The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. A randomized open clinical trial was developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir
Description: The aim of the study was to identify the incidence of MetS at 48 weeks for ATP III score in patients living with HIV (PLH) who started antiretroviral therapy (ART) with Dolutegravir based-regimen compared with Bictegravir based-regimen. A randomized open clinical trial was developed with men PLH who started ART randomized to BIC/FTC/TAF or DTG/3TC/ABC.
Study: NCT06365554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remedy Robot
Description: A trained Neurointerventionalist will operate the Remedy Robot from a computer-based user interface in a room adjacent to the patient. An entire cerebral angiogram or cerebral embolization will be performed, excluding insertion and removal of the femoral sheath.
Study: NCT04872153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dividat Senso Exergames
Description: The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.~Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min).
Study: NCT04659239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell)
Description: The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
Study: NCT06286280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cytokine adsorber (CytoSorb®)
Description: binding of cytokines to the sorbent polystyrene of the adsorber during cardiac surgery with extracorporeal circulation
Study: NCT05742464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RUBI
Description: RUBI teaches caregivers a range of skills to support the building of a behavioral management toolbox. The intervention emphasizes: 1) tailoring the intervention to the child; 2) identifying behavioral function instead of topography as a means to inform behavioral strategy choice (i.e., targeting what is driving the behavior, instead of the behavior itself); 3) decreasing behavioral excess as well as increasing appropriate behaviors; and 4) using positive behavioral supports, such as antecedent management (e.g. use of visual supports), reinforcement, and functional communication strategies as the means to modify behaviors. RUBI uses a behavioral skills training approach, which includes direct instruction, modeling, role-play and practice with feedback in order to train caregivers in the various RUBI skills. Sessions also have accompanying video vignettes that are used to illustrate skills or test parental understanding of session materials.
Study: NCT04895306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Weekly intramuscular administration of testosterone at a dose of 3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly intramuscular administration of Placebo
Study: NCT05005169

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SGB PCR
Description: This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SGB culture
Description: This is a multi-center, randomized cluster and crossover study, and is open-label. The cluster is defined by the hospital center. Each center will therefore experiment with both strategies and the hospital centers will be randomized according to two arms:~* Arm n°1 : 1st period with SGB culture strategy and 2nd period with SGB PCR strategy.~* Arm n°2 : 1st period with SGB PCR Strategy and 2nd period with SGB culture Strategy Each inclusion period will last 6 weeks, with a 1-month wash-in period before each of the two inclusion periods of the study (training of the teams in intrapartum PCR detection). A wash-out period is not necessary in this study because the PCR machine will be removed from the centers when switching to the GBS culture strategy.~During these two periods, all patients meeting the inclusion and non-inclusion criteria will be included in the study after presentation of the study and oral consent.
Study: NCT05448066

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Component resolved diagnosis
Description: Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
Study: NCT05296733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: BI 456906
Study: NCT05448066

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard diagnosis
Description: Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
Study: NCT06652984

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 1
Description: Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 2
Description: Patients were planned to complete exercise sessions 5 times a week for 12 weeks, each lasting 35 minutes per day.
Study: NCT05567159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donanemab
Description: Administered IV.
Study: NCT06141239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Tooth Root
Description: An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Tooth Root
Description: An autologous Tooth Root is made from one's own tooth root and covered in an extraction socket where bone graft is placed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit.D3
Description: Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit.D3
Description: Local administration of Vit.D3, through the effect of Vit.D3 to explore whether it can help to accelerate the healing of tooth extraction cavity and the clinical effectiveness of bone regeneration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Selecting bone materials for alveolar ridge preservation according to treatment needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Selecting bone materials for alveolar ridge preservation according to treatment needs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone graft
Description: Selecting bone materials for alveolar ridge preservation according to treatment needs
Study: NCT06609876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Description: Thermal ablation of tumors

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Description: Thermal ablation of tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib ( 100 mg，bid)
Study: NCT05279963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: The prespecified acupoints applied here will include bilateral Sanyinjiao(SP6), Shenshu(BL23), Ciliao(BL32), Zhongliao(BL33), Zhibian(BL54) .~Acupuncture treatment is carried out by acupuncturists who have been well trained. Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China). Electroacupuncture procedures will be performed with electronic instruments (Hans-100A, Nanjing Jisheng Medical TechnologyCo., Ltd, China). Two paired of acupoints (i.e., two Shenshu(BL23) and two Ciliao(BL32), respectively) are connected to the EA apparatus. Alternating-frequency mode is selected and frequency is 2/100 Hz. EA intensity is determined in accordance with patients' endurance. EA will last for 30 min for each treatment. Patients will receive a total number of 12 EA sessions, with the frequency of 3 sessions per week for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Participants in the medication group will be merely treated with oral administration of amitriptyline capsule. The dosage of amitriptyline is 25mg bid, for 4 weeks. Any changes in the medications of individual participants will be recorded on diary cards.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: In the trunk region, the points are 5 cm away from respective acupoints. In the lower limb region, the point is 3 cm away from Sanyinjiao(SP6). All points will only receive shallow insertion.~Acupuncture will be performed with disposable and sterile needles in the specification of 0.25 ×40 mm(diameter: 0.25mm; Suzhou Medical Products Factory Co., Ltd, China).The needles are shallowly inserted to the subcutaneous area, and acupoints are connected to the EA apparatus without electricity. The frequency, intensity and duration of treatment will be the same as the electric needle group.
Study: NCT06614985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Subcutaneous injection of 160 mg is administered once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Subcutaneous injection of 160 mg is administered once a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Induction therapy period (3 months)：Eligible subjects receive induction treatment with Methylprednisone 0.5 g i. v. for 3 consecutive day and followed by orally administration of prednisone at an initial dose of 0.8 mg/kg/day, tapered gradually after 2 months (reduced by 5 mg every 2 weeks) Grouped treatment period (6 months): The maintenance induction treatment regimen is continued, with regular tapering (reducing by 5 mg every 2 weeks) until discontinuation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: An intravenous injection of 0.4 g is administered twice a month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: An intravenous injection of 0.4 g is administered twice a month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: An intravenous injection of 0.4 g is administered twice a month.
Study: NCT06613399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTI-TME
Description: Multi-Technology Tntegrated Total Mesorectal Excision，MTI-TME

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: C-TME
Description: Conventional Total Mesorectal Excision，C-TME
Study: NCT06615453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermo-mechanical action based peri-orbital fractional skin treatment
Description: Participants will receive three Tixel® treatments at 2-weeks intervals

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Participants will receive three sham treatments at 2-weeks intervals
Study: NCT06613932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: removal of the coronal pulp tissue and preservation of the radicular portion to ensure continuation of growth and vitality of tooth structure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: removal of the coronal pulp tissue and preservation of the radicular portion to ensure continuation of growth and vitality of tooth structure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: removal of the coronal pulp tissue and preservation of the radicular portion to ensure continuation of growth and vitality of tooth structure
Study: NCT05218915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Dulaglutide once weekly subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin degludec once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Insulin degludec once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitor
Description: Dexcom G6 CGM system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Dexcom G6 CGM system
Study: NCT05732818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQdisc Nucleus Replacement System
Description: Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
Study: NCT05468658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Designing the birthing unit according to the philosophy of Feng Shui
Description: 1. The cabinets will be painted using salmon and pastel green.~2. It is planned to make designs specific to the philosophy of Feng Shui on the doors and walls of the birthing unit.~3. Live nature videos and sounds will be projected onto the wall.~4. Fabric curtains will be replaced with curtains designed according to the philosophy of Feng Shui.~5. Natural plants will be placed.~6. Lighting will be used.~7. Bed linen will be designed according to the Feng Shui.~8. Wooden bell will be used.~9. Turtle, elephant and Wu Lou objects will be placed.~10. The Bagua mirror will be placed.~11. Crystals will be placed.~12. Natural stones will be placed.~13. The fountain will be placed in the east compass direction of the unit.~14. Straw bamboo separator will be used.
Study: NCT05397470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: Losmapimod 15 mg will be administered BID by mouth along with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: Losmapimod 15 mg will be administered BID by mouth along with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be administered BID by mouth along with food.